The RTP operation of Diosynth will supply the active pharmaceutical ingredient for a hormone disorder drug to Pfizer.

Akzo Nobel and Pfizer announced a multi-year contract on Monday for production and delivery of the ingredient that is part of Somavert. Terms were not disclosed, but Azko Nobel said the contract would “contribute significantly” to its Diosynth business unit’s income.